Rinvoq Gains FDA Approval for Atopic Dermatitis : vimarsana.

The FDA has approved Rinvoq (upadacitinib) for the treatment of refractory, moderate to severe atopic dermatitis in patients 12 years of age and older.

Related Keywords

Thomas Hudson , Drug Administration , Eczema Area Severity Index , Global Assessment , Atopic Dermatitis , Worst Pruritus Numerical Rating Scale , Worst Pruritus , Safety Communication ,